Adult grade II diffuse @entity816 are genetically distinct from and more XXXX than their paediatric counterparts.

@entity1 @entity1841 @entity146 @entity5 @entity876 @entity8724 @entity818 @entity2843 @entity816 @entity74 @entity8725 @entity38765 @entity34519 @entity27135
Diffuse @entity816 (WHO grade II) typically present as slow-growing @entity5 showing significant cellular differentiation, but possessing a tendency towards malignant progression. They account for ~10% of all @entity5 , with a peak incidence between 30 and 40 years of age. Median survival is reported as around 6-8 years. Mutations of @entity876 and @entity818 have been described as @entity74 , while copy number alterations are also relatively common. However, there is some evidence to suggest that these characteristics may vary with age. Here, we present an integrated clinicopathologic, genomic and transcriptomic analysis suggesting that @entity5 are associated with distinct genetic signatures. For example, no childhood @entity5 showed mutation of @entity8725 or @entity876 , virtually no copy number changes were seen, and @entity8724 methylation was absent. In contrast, @entity5 showed @entity8725 mutation in 94% and @entity876 mutation in 69% of cases, with multiple copy number alterations per case and hypermethylation of @entity8724 in the majority of @entity5 . These differences were associated with a worse prognosis in the adult @entity1 . The expression array data also revealed a significant difference in the expression of a number of genes putatively involved in neural stem cell maintenance and CNS development, including @entity38765 , @entity34519 , @entity1841 , @entity2843 and @entity27135 . Genes involved in DNA replication and the cell cycle were also enriched in the @entity5 , suggesting that their more @entity146 may be due to derivation from a more rapidly dividing, less differentiated cell type.
